APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchBiosimilars Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilars Segment by Company

Teva Pharmaceutical

Samsung Biologics

Novartis

Merck KgaA

Mylan

Roche

Eli Lilly

Pfizer

Gan & Lee Pharmaceuticals

Biogen

Amgen

Stada Arzneimittel AG

Probiomed

JCR Pharmaceuticals

Gedeon Richter

Fresenius Kabi AG

Dr. Reddy's Laboratories

Coherus Bioscience

Chong Kun Dang

Celltrion

Boehringer Ingelheim

Biocon

Biocad

Apotex

Biosimilars Segment by Type

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Recombinant Glycosylated Proteins

Biosimilars Segment by Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biosimilars Industry Trends Table 2. Biosimilars Industry Drivers Table 3. Biosimilars Industry Opportunities and Challenges Table 4. Biosimilars Industry Restraints Table 5. Global Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biosimilars Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Biosimilars Sales Market Share by Manufacturers Table 9. Global Biosimilars Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biosimilars Manufacturers, Product Type & Application Table 13. Global Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Table 17. Major Manufacturers of Recombinant Glycosylated Proteins Table 18. Global Biosimilars Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Biosimilars Sales by Type (2021-2026) & (k units) Table 20. Global Biosimilars Sales by Type (2027-2032) & (k units) Table 21. Global Biosimilars Sales Market Share by Type (2021-2026) Table 22. Global Biosimilars Sales Market Share by Type (2027-2032) Table 23. Global Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Biosimilars Revenue by Type (2021-2026) & (k units) Table 25. Global Biosimilars Revenue by Type (2027-2032) & (k units) Table 26. Global Biosimilars Revenue Market Share by Type (2021-2026) Table 27. Global Biosimilars Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Oncology Table 29. Major Manufacturers of Blood Disorders Table 30. Major Manufacturers of Growth Hormonal Deficiency Table 31. Major Manufacturers of Chronic and Autoimmune Disorders Table 32. Major Manufacturers of Others Table 33. Global Biosimilars Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Biosimilars Sales by Application (2021-2026) & (k units) Table 35. Global Biosimilars Sales by Application (2027-2032) & (k units) Table 36. Global Biosimilars Sales Market Share by Application (2021-2026) Table 37. Global Biosimilars Sales Market Share by Application (2027-2032) Table 38. Global Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Biosimilars Revenue by Application (2021-2026) & (k units) Table 40. Global Biosimilars Revenue by Application (2027-2032) & (k units) Table 41. Global Biosimilars Revenue Market Share by Application (2021-2026) Table 42. Global Biosimilars Revenue Market Share by Application (2027-2032) Table 43. Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Biosimilars Sales by Region (2021-2026) & (k units) Table 45. Global Biosimilars Sales Market Share by Region (2021-2026) Table 46. Global Biosimilars Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Biosimilars Sales by Country (2021-2026) & (k units) Table 50. North America Biosimilars Sales by Country (2027-2032) & (k units) Table 51. Europe Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Biosimilars Sales by Country (2021-2026) & (k units) Table 53. Europe Biosimilars Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Biosimilars Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Biosimilars Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Biosimilars Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Biosimilars Sales by Country (2027-2032) & (k units) Table 60. Global Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Biosimilars Revenue Market Share by Region (2021-2026) Table 64. Global Biosimilars Revenue Market Share by Region (2027-2032) Table 65. Teva Pharmaceutical Company Information Table 66. Teva Pharmaceutical Business Overview Table 67. Teva Pharmaceutical Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Biosimilars Product Portfolio Table 69. Teva Pharmaceutical Recent Development Table 70. Samsung Biologics Company Information Table 71. Samsung Biologics Business Overview Table 72. Samsung Biologics Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Samsung Biologics Biosimilars Product Portfolio Table 74. Samsung Biologics Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis Biosimilars Product Portfolio Table 79. Novartis Recent Development Table 80. Merck KgaA Company Information Table 81. Merck KgaA Business Overview Table 82. Merck KgaA Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck KgaA Biosimilars Product Portfolio Table 84. Merck KgaA Recent Development Table 85. Mylan Company Information Table 86. Mylan Business Overview Table 87. Mylan Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Mylan Biosimilars Product Portfolio Table 89. Mylan Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Roche Biosimilars Product Portfolio Table 94. Roche Recent Development Table 95. Eli Lilly Company Information Table 96. Eli Lilly Business Overview Table 97. Eli Lilly Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Eli Lilly Biosimilars Product Portfolio Table 99. Eli Lilly Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Pfizer Biosimilars Product Portfolio Table 104. Pfizer Recent Development Table 105. Gan & Lee Pharmaceuticals Company Information Table 106. Gan & Lee Pharmaceuticals Business Overview Table 107. Gan & Lee Pharmaceuticals Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Gan & Lee Pharmaceuticals Biosimilars Product Portfolio Table 109. Gan & Lee Pharmaceuticals Recent Development Table 110. Biogen Company Information Table 111. Biogen Business Overview Table 112. Biogen Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Biogen Biosimilars Product Portfolio Table 114. Biogen Recent Development Table 115. Amgen Company Information Table 116. Amgen Business Overview Table 117. Amgen Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Amgen Biosimilars Product Portfolio Table 119. Amgen Recent Development Table 120. Stada Arzneimittel AG Company Information Table 121. Stada Arzneimittel AG Business Overview Table 122. Stada Arzneimittel AG Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Stada Arzneimittel AG Biosimilars Product Portfolio Table 124. Stada Arzneimittel AG Recent Development Table 125. Probiomed Company Information Table 126. Probiomed Business Overview Table 127. Probiomed Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Probiomed Biosimilars Product Portfolio Table 129. Probiomed Recent Development Table 130. JCR Pharmaceuticals Company Information Table 131. JCR Pharmaceuticals Business Overview Table 132. JCR Pharmaceuticals Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. JCR Pharmaceuticals Biosimilars Product Portfolio Table 134. JCR Pharmaceuticals Recent Development Table 135. Gedeon Richter Company Information Table 136. Gedeon Richter Business Overview Table 137. Gedeon Richter Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Gedeon Richter Biosimilars Product Portfolio Table 139. Gedeon Richter Recent Development Table 140. Fresenius Kabi AG Company Information Table 141. Fresenius Kabi AG Business Overview Table 142. Fresenius Kabi AG Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Fresenius Kabi AG Biosimilars Product Portfolio Table 144. Fresenius Kabi AG Recent Development Table 145. Dr. Reddy's Laboratories Company Information Table 146. Dr. Reddy's Laboratories Business Overview Table 147. Dr. Reddy's Laboratories Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Dr. Reddy's Laboratories Biosimilars Product Portfolio Table 149. Dr. Reddy's Laboratories Recent Development Table 150. Coherus Bioscience Company Information Table 151. Coherus Bioscience Business Overview Table 152. Coherus Bioscience Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Coherus Bioscience Biosimilars Product Portfolio Table 154. Coherus Bioscience Recent Development Table 155. Chong Kun Dang Company Information Table 156. Chong Kun Dang Business Overview Table 157. Chong Kun Dang Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Chong Kun Dang Biosimilars Product Portfolio Table 159. Chong Kun Dang Recent Development Table 160. Celltrion Company Information Table 161. Celltrion Business Overview Table 162. Celltrion Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Celltrion Biosimilars Product Portfolio Table 164. Celltrion Recent Development Table 165. Boehringer Ingelheim Company Information Table 166. Boehringer Ingelheim Business Overview Table 167. Boehringer Ingelheim Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Boehringer Ingelheim Biosimilars Product Portfolio Table 169. Boehringer Ingelheim Recent Development Table 170. Biocon Company Information Table 171. Biocon Business Overview Table 172. Biocon Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Biocon Biosimilars Product Portfolio Table 174. Biocon Recent Development Table 175. Biocad Company Information Table 176. Biocad Business Overview Table 177. Biocad Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Biocad Biosimilars Product Portfolio Table 179. Biocad Recent Development Table 180. Apotex Company Information Table 181. Apotex Business Overview Table 182. Apotex Biosimilars Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Apotex Biosimilars Product Portfolio Table 184. Apotex Recent Development Table 185. Key Raw Materials Table 186. Raw Materials Key Suppliers Table 187. Biosimilars Distributors List Table 188. Biosimilars Customers List Table 189. Research Programs/Design for This Report Table 190. Authors List of This Report Table 191. Secondary Sources Table 192. Primary Sources List of Figures Figure 1. Biosimilars Product Image Figure 2. Global Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilars Sales (2021-2032) & (k units) Figure 5. Global Biosimilars Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Image Figure 9. Recombinant Glycosylated Proteins Image Figure 10. Global Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Biosimilars Sales Market Share by Type (2021-2032) Figure 13. Global Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Biosimilars Revenue Market Share by Type (2021-2032) Figure 16. Oncology Image Figure 17. Blood Disorders Image Figure 18. Growth Hormonal Deficiency Image Figure 19. Chronic and Autoimmune Disorders Image Figure 20. Others Image Figure 21. Global Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Biosimilars Sales Market Share by Application (2021-2032) Figure 24. Global Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Biosimilars Revenue Market Share by Application (2021-2032) Figure 27. North America Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Biosimilars Sales Market Share by Country (2021-2032) Figure 29. U.S. Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Biosimilars Sales Market Share by Country (2021-2032) Figure 34. Germany Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Biosimilars Sales Market Share by Country (2021-2032) Figure 41. China Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Biosimilars Sales Market Share by Country (2021-2032) Figure 49. Brazil Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Biosimilars Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Biosimilars Revenue (2021-2032) & (US$ Million) Figure 60. North America Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Biosimilars Revenue (2021-2032) & (US$ Million) Figure 62. Europe Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Biosimilars Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Biosimilars Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Biosimilars Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Biosimilars Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins
Applications
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others
Companies covered
  • Teva Pharmaceutical
  • Samsung Biologics
  • Novartis
  • Merck KgaA
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Gan & Lee Pharmaceuticals
  • Biogen
  • Amgen
  • Stada Arzneimittel AG
  • Probiomed
  • JCR Pharmaceuticals
  • Gedeon Richter
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories
  • Coherus Bioscience
  • Chong Kun Dang
  • Celltrion
  • Boehringer Ingelheim
  • Biocon
  • Biocad
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biosimilars Market Dynamics
  1. 2.1 Biosimilars Industry Trends
  2. 2.2 Biosimilars Industry Drivers
  3. 2.3 Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biosimilars Industry Restraints
3 Biosimilars Market by Manufacturers
  1. 3.1 Global Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilars Tier 1, Tier 2, and Tier 3
4 Biosimilars Market by Type
  1. 4.1 Biosimilars Type Introduction
  2. 4.1.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  3. 4.1.2 Recombinant Glycosylated Proteins
  4. 4.2 Global Biosimilars Sales by Type
  5. 4.2.1 Global Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Biosimilars Sales by Type (2021-2032)
  7. 4.2.3 Global Biosimilars Sales Market Share by Type (2021-2032)
  8. 4.3 Global Biosimilars Revenue by Type
  9. 4.3.1 Global Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Biosimilars Revenue by Type (2021-2032)
  11. 4.3.3 Global Biosimilars Revenue Market Share by Type (2021-2032)
5 Biosimilars Market by Application
  1. 5.1 Biosimilars Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Blood Disorders
  4. 5.1.3 Growth Hormonal Deficiency
  5. 5.1.4 Chronic and Autoimmune Disorders
  6. 5.1.5 Others
  7. 5.2 Global Biosimilars Sales by Application
  8. 5.2.1 Global Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Biosimilars Sales by Application (2021-2032)
  10. 5.2.3 Global Biosimilars Sales Market Share by Application (2021-2032)
  11. 5.3 Global Biosimilars Revenue by Application
  12. 5.3.1 Global Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Biosimilars Revenue by Application (2021-2032)
  14. 5.3.3 Global Biosimilars Revenue Market Share by Application (2021-2032)
6 Global Biosimilars Sales by Region
  1. 6.1 Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biosimilars Revenue by Region
  1. 7.1 Global Biosimilars Revenue by Region
  2. 7.1.1 Global Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Samsung Biologics
  8. 8.2.1 Samsung Biologics Company Information
  9. 8.2.2 Samsung Biologics Business Overview
  10. 8.2.3 Samsung Biologics Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Biologics Biosimilars Product Portfolio
  12. 8.2.5 Samsung Biologics Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biosimilars Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck KgaA
  20. 8.4.1 Merck KgaA Company Information
  21. 8.4.2 Merck KgaA Business Overview
  22. 8.4.3 Merck KgaA Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck KgaA Biosimilars Product Portfolio
  24. 8.4.5 Merck KgaA Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Biosimilars Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Biosimilars Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Biosimilars Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Biosimilars Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Gan & Lee Pharmaceuticals
  50. 8.9.1 Gan & Lee Pharmaceuticals Company Information
  51. 8.9.2 Gan & Lee Pharmaceuticals Business Overview
  52. 8.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
  54. 8.9.5 Gan & Lee Pharmaceuticals Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Biosimilars Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Biosimilars Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Stada Arzneimittel AG
  68. 8.12.1 Stada Arzneimittel AG Company Information
  69. 8.12.2 Stada Arzneimittel AG Business Overview
  70. 8.12.3 Stada Arzneimittel AG Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
  72. 8.12.5 Stada Arzneimittel AG Recent Developments
  73. 8.13 Probiomed
  74. 8.13.1 Probiomed Company Information
  75. 8.13.2 Probiomed Business Overview
  76. 8.13.3 Probiomed Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Probiomed Biosimilars Product Portfolio
  78. 8.13.5 Probiomed Recent Developments
  79. 8.14 JCR Pharmaceuticals
  80. 8.14.1 JCR Pharmaceuticals Company Information
  81. 8.14.2 JCR Pharmaceuticals Business Overview
  82. 8.14.3 JCR Pharmaceuticals Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
  84. 8.14.5 JCR Pharmaceuticals Recent Developments
  85. 8.15 Gedeon Richter
  86. 8.15.1 Gedeon Richter Company Information
  87. 8.15.2 Gedeon Richter Business Overview
  88. 8.15.3 Gedeon Richter Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Gedeon Richter Biosimilars Product Portfolio
  90. 8.15.5 Gedeon Richter Recent Developments
  91. 8.16 Fresenius Kabi AG
  92. 8.16.1 Fresenius Kabi AG Company Information
  93. 8.16.2 Fresenius Kabi AG Business Overview
  94. 8.16.3 Fresenius Kabi AG Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
  96. 8.16.5 Fresenius Kabi AG Recent Developments
  97. 8.17 Dr. Reddy's Laboratories
  98. 8.17.1 Dr. Reddy's Laboratories Company Information
  99. 8.17.2 Dr. Reddy's Laboratories Business Overview
  100. 8.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
  102. 8.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 8.18 Coherus Bioscience
  104. 8.18.1 Coherus Bioscience Company Information
  105. 8.18.2 Coherus Bioscience Business Overview
  106. 8.18.3 Coherus Bioscience Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Coherus Bioscience Biosimilars Product Portfolio
  108. 8.18.5 Coherus Bioscience Recent Developments
  109. 8.19 Chong Kun Dang
  110. 8.19.1 Chong Kun Dang Company Information
  111. 8.19.2 Chong Kun Dang Business Overview
  112. 8.19.3 Chong Kun Dang Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Chong Kun Dang Biosimilars Product Portfolio
  114. 8.19.5 Chong Kun Dang Recent Developments
  115. 8.20 Celltrion
  116. 8.20.1 Celltrion Company Information
  117. 8.20.2 Celltrion Business Overview
  118. 8.20.3 Celltrion Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Celltrion Biosimilars Product Portfolio
  120. 8.20.5 Celltrion Recent Developments
  121. 8.21 Boehringer Ingelheim
  122. 8.21.1 Boehringer Ingelheim Company Information
  123. 8.21.2 Boehringer Ingelheim Business Overview
  124. 8.21.3 Boehringer Ingelheim Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
  126. 8.21.5 Boehringer Ingelheim Recent Developments
  127. 8.22 Biocon
  128. 8.22.1 Biocon Company Information
  129. 8.22.2 Biocon Business Overview
  130. 8.22.3 Biocon Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Biocon Biosimilars Product Portfolio
  132. 8.22.5 Biocon Recent Developments
  133. 8.23 Biocad
  134. 8.23.1 Biocad Company Information
  135. 8.23.2 Biocad Business Overview
  136. 8.23.3 Biocad Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Biocad Biosimilars Product Portfolio
  138. 8.23.5 Biocad Recent Developments
  139. 8.24 Apotex
  140. 8.24.1 Apotex Company Information
  141. 8.24.2 Apotex Business Overview
  142. 8.24.3 Apotex Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Apotex Biosimilars Product Portfolio
  144. 8.24.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilars Value Chain Analysis
  2. 9.1.1 Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilars Production Mode & Process
  6. 9.2 Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilars Distributors
  9. 9.2.3 Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst